In anticipation of the 2017 G20 Summit in Hamburg, Germany, on 7-8 July, the DRIVE-AB Steering Committee has published a commentary in The Lancet Infectious Diseases today, 6 July, titled "To the G20 – Next steps for incentivizing antibacterial R&D". The commentary outlines a sample of preliminary recommendations and next steps that are relevant to the ongoing G20 proceedings and to G20 leaders. More detailed results and recommendations from the DRIVE-AB consortium as a whole will be presented at the final DRIVE-AB conference, "Revitalizing the Antibiotic Pipeline", in Brussels on 5-6 September 2017.
DRIVE-AB regrets that ReAct has decided to leave the DRIVE-AB partnership. We believe that ReAct has contributed positively to the conversations and development of DRIVE-AB’s research. With ReAct leaving, we lose an important voice within the project to represent civil society. DRIVE-AB (www.drive-ab.eu) has been from the start a public-private partnership including 22 partners from large pharmaceutical companies, academia, and civil society, in other words, a contrasting mix of people with different experience, expertise and visions. This is the strength and the originality of the project, but also represents its major challenge. As the project developed, DRIVE-AB has had to adapt to a fast-moving environment due to political...Read more
The World Health Organization has developed a global open-access tripartite antimicrobial resistance database. The database provides access to baseline information on the status of countries regarding their respective progress on the implementation of the World Health Organization Global Action Plan on Antimicrobial Resistance. Click here to read more and view the database....Read more
Revitalizing the Antibiotic Pipeline
Stimulating innovation while driving sustainable use and global access 5-6 September 2017, Crowne Plaza, BrusselsRegistration for the final DRIVE-AB conference is now open. Aimed at global policy and decision makers, regulatory and public health experts, economists and representatives of the pharmaceutical, medical and civil society communities, the purpose of the conference is to:
- communicate the consortium’s final recommendations and
- work with stakeholders towards implementing them worldwide.
The Inter-Agency Coordination Group (IACG) on AMR established by the UN Secretary-General met for the first time on the 2nd and 3rd of May. The group, comprised of high-level representatives from relevant UN agencies, individual experts, and other international organizations, is tasked with providing practical guidance on approaches to implement and ensure effective global action to address AMR, including options to improve coordination, fulfill the Global Action Plan on Antimicrobial Resistance, and implement Sustainable Development Goals. The IACG is expected to produce a report to the Secretary-General for the 73rd session of the UN General Assembly. DRIVE-AB partner Otto Cars attended the meeting as an individual expert.